{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:12:22Z","timestamp":1765995142067,"version":"3.48.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100006742","name":"Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio","doi-asserted-by":"publisher","award":["GBMM-Multi3D"],"award-info":[{"award-number":["GBMM-Multi3D"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006742","name":"Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio","doi-asserted-by":"publisher","award":["GLIMFOX_GI2-CESPU-2025"],"award-info":[{"award-number":["GLIMFOX_GI2-CESPU-2025"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"'la Caixa' Foundation","doi-asserted-by":"publisher","award":["HR25_00392"],"award-info":[{"award-number":["HR25_00392"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"name":"FUnda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","award":["2020.06611.BD"],"award-info":[{"award-number":["2020.06611.BD"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"DOI":"10.1007\/s13346-025-02025-1","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:10:27Z","timestamp":1765995027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rational design of anticancer multidrug nanosystems and their adaptation for glioblastoma treatment"],"prefix":"10.1007","author":[{"given":"Catarina","family":"Pacheco","sequence":"first","affiliation":[]},{"given":"F\u00e1tima","family":"Baltazar","sequence":"additional","affiliation":[]},{"given":"Bruno M.","family":"Costa","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5763-7553","authenticated-orcid":false,"given":"Bruno","family":"Sarmento","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"2025_CR1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.77.6112","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/jco.2017.77.6112.","journal-title":"J Clin Oncol"},{"key":"2025_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00134-4","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021. https:\/\/doi.org\/10.1016\/s2352-3026(21)00134-4.","journal-title":"Lancet Haematol"},{"key":"2025_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.06.028","author":"P Tardi","year":"2009","unstructured":"Tardi P, Johnstone S, Harasym N, Xie S, Harasym T, Zisman N, et al. In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. Leuk Res. 2009. https:\/\/doi.org\/10.1016\/j.leukres.2008.06.028.","journal-title":"Leuk Res"},{"key":"2025_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2012.07.006","author":"EJ Feldman","year":"2012","unstructured":"Feldman EJ, Kolitz JE, Trang JM, Liboiron BD, Swenson CE, Chiarella MT, et al. Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia. Leuk Res. 2012. https:\/\/doi.org\/10.1016\/j.leukres.2012.07.006.","journal-title":"Leuk Res"},{"key":"2025_CR5","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.5b02913","author":"KM Au","year":"2015","unstructured":"Au KM, Min Y, Tian X, Zhang L, Perello V, Caster JM, et al. Improving cancer chemoradiotherapy treatment by dual controlled release of Wortmannin and Docetaxel in polymeric nanoparticles. ACS Nano. 2015. https:\/\/doi.org\/10.1021\/acsnano.5b02913.","journal-title":"ACS Nano"},{"key":"2025_CR6","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.0c12042","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Fu X, Jia J, Wikerholmen T, Xi K, Kong Y, et al. Glioblastoma therapy using codelivery of Cisplatin and glutathione peroxidase targeting siRNA from iron oxide nanoparticles. ACS Appl Mater Interfaces. 2020. https:\/\/doi.org\/10.1021\/acsami.0c12042.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2025_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202000013","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhang Y, Ding X, Shen W, Li M, Wagner E, et al. A multistage cooperative nanoplatform enables intracellular co-delivery of proteins and chemotherapeutics for cancer therapy. Adv Mater. 2020. https:\/\/doi.org\/10.1002\/adma.202000013.","journal-title":"Adv Mater"},{"key":"2025_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba8564","author":"KM Au","year":"2020","unstructured":"Au KM, Park SI, Wang AZ. Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. Sci Adv. 2020. https:\/\/doi.org\/10.1126\/sciadv.aba8564.","journal-title":"Sci Adv"},{"key":"2025_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202209785","author":"X Xu","year":"2023","unstructured":"Xu X, Zhang Z, Du J, Xue Y, Chen X, Zhang J, et al. Recruiting T-cells toward the brain for enhanced glioblastoma immunotherapeutic efficacy by co-delivery of cytokines and immune checkpoint antibodies with macrophage-membrane-camouflaged nanovesicles. Adv Mater. 2023. https:\/\/doi.org\/10.1002\/adma.202209785.","journal-title":"Adv Mater"},{"key":"2025_CR10","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.081065198","author":"DJ Stephens","year":"2001","unstructured":"Stephens DJ, Pepperkok R. The many ways to cross the plasma membrane. Proc Natl Acad Sci U S A. 2001. https:\/\/doi.org\/10.1073\/pnas.081065198.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-023-02147-z","author":"SS Ali Zaidi","year":"2023","unstructured":"Ali Zaidi SS, Fatima F, Ali Zaidi SA, Zhou D, Deng W, Liu S. Engineering siRNA therapeutics: challenges and strategies. J Nanobiotechnology. 2023. https:\/\/doi.org\/10.1186\/s12951-023-02147-z.","journal-title":"J Nanobiotechnology"},{"key":"2025_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/smll.201000631","author":"S Aryal","year":"2010","unstructured":"Aryal S, Hu CM, Zhang L. Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small. 2010. https:\/\/doi.org\/10.1002\/smll.201000631.","journal-title":"Small"},{"key":"2025_CR13","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.0c05028","author":"F Yu","year":"2021","unstructured":"Yu F, Tu Y, Luo S, Xiao X, Yao W, Jiang M, et al. Dual-drug backboned polyprodrug with a predefined drug combination for synergistic chemotherapy. Nano Lett. 2021. https:\/\/doi.org\/10.1021\/acs.nanolett.0c05028.","journal-title":"Nano Lett"},{"key":"2025_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201702342","author":"M Ye","year":"2017","unstructured":"Ye M, Han Y, Tang J, Piao Y, Liu X, Zhou Z, et al. A tumor-specific cascade amplification drug release nanoparticle for overcoming multidrug resistance in cancers. Adv Mater. 2017. https:\/\/doi.org\/10.1002\/adma.201702342.","journal-title":"Adv Mater"},{"key":"2025_CR15","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"2025_CR16","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21613","author":"AC Tan","year":"2020","unstructured":"Tan AC, Ashley DM, L\u00f3pez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: state of the art and future directions. CA Cancer J Clin. 2020. https:\/\/doi.org\/10.3322\/caac.21613.","journal-title":"CA Cancer J Clin"},{"key":"2025_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2019.11.009","author":"R Pandit","year":"2020","unstructured":"Pandit R, Chen L, G\u00f6tz J. The blood-brain barrier: physiology and strategies for drug delivery. Adv Drug Deliv Rev. 2020. https:\/\/doi.org\/10.1016\/j.addr.2019.11.009.","journal-title":"Adv Drug Deliv Rev"},{"key":"2025_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.12.013","author":"R Mathur","year":"2024","unstructured":"Mathur R, Wang Q, Schupp PG, Nikolic A, Hilz S, Hong C, et al. Glioblastoma evolution and heterogeneity from a 3D whole-tumor perspective. Cell. 2024. https:\/\/doi.org\/10.1016\/j.cell.2023.12.013.","journal-title":"Cell"},{"key":"2025_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.05.001","author":"I Marin-Valencia","year":"2012","unstructured":"Marin-Valencia I, Yang C, Mashimo T, Cho S, Baek H, Yang XL, et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell Metab. 2012. https:\/\/doi.org\/10.1016\/j.cmet.2012.05.001.","journal-title":"Cell Metab"},{"key":"2025_CR20","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1106704108","author":"E Vlashi","year":"2011","unstructured":"Vlashi E, Lagadec C, Vergnes L, Matsutani T, Masui K, Poulou M, et al. Metabolic state of glioma stem cells and nontumorigenic cells. Proc Natl Acad Sci U S A. 2011. https:\/\/doi.org\/10.1073\/pnas.1106704108.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00547-6","author":"L van Hooren","year":"2023","unstructured":"van Hooren L, Handgraaf SM, Kloosterman DJ, Karimi E, van Mil L, Gassama AA, et al. CD103(+) regulatory T cells underlie resistance to radio-immunotherapy and impair CD8(+) T cell activation in glioblastoma. Nat Cancer. 2023. https:\/\/doi.org\/10.1038\/s43018-023-00547-6.","journal-title":"Nat Cancer"},{"key":"2025_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.509","author":"P Dahan","year":"2014","unstructured":"Dahan P, Martinez Gala J, Delmas C, Monferran S, Malric L, Zentkowski D, et al. Ionizing radiations sustain glioblastoma cell dedifferentiation to a stem-like phenotype through survivin: possible involvement in radioresistance. Cell Death Dis. 2014. https:\/\/doi.org\/10.1038\/cddis.2014.509.","journal-title":"Cell Death Dis"},{"key":"2025_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202510004","author":"X Zhou","year":"2025","unstructured":"Zhou X, Deng R, Liao Z, Huang X, Huang J, Yang H, et al. Integrating metabolic modulation and nanomedicine for cancer immunotherapy. Adv Sci. 2025. https:\/\/doi.org\/10.1002\/advs.202510004.","journal-title":"Adv Sci"},{"key":"2025_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201801362","author":"D Furtado","year":"2018","unstructured":"Furtado D, Bj\u00f6rnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases. Adv Mater. 2018. https:\/\/doi.org\/10.1002\/adma.201801362.","journal-title":"Adv Mater"},{"key":"2025_CR25","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c00320","author":"W He","year":"2022","unstructured":"He W, Li X, Morsch M, Ismail M, Liu Y, Rehman FU, et al. Brain-targeted codelivery of Bcl-2\/Bcl-xl and Mcl-1 inhibitors by biomimetic nanoparticles for orthotopic glioblastoma therapy. ACS Nano. 2022. https:\/\/doi.org\/10.1021\/acsnano.2c00320.","journal-title":"ACS Nano"},{"key":"2025_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-44963-3","author":"Z Zhang","year":"2024","unstructured":"Zhang Z, Xu X, Du J, Chen X, Xue Y, Zhang J, et al. Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-44963-3.","journal-title":"Nat Commun"},{"key":"2025_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201600417","author":"C Song","year":"2016","unstructured":"Song C, Zhang Y, Li C, Chen G, Kang X, Wang Q. Enhanced nanodrug delivery to solid tumors based on a tumor vasculature-targeted strategy. Adv Funct Mater. 2016. https:\/\/doi.org\/10.1002\/adfm.201600417.","journal-title":"Adv Funct Mater"},{"key":"2025_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.02.018","author":"M Heuser","year":"2020","unstructured":"Heuser M, Ofran Y, Boissel N, Brunet Mauri S, Craddock C, Janssen J, et al. Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.018.","journal-title":"Ann Oncol"},{"key":"2025_CR29","doi-asserted-by":"publisher","DOI":"10.2147\/ijn.S139450","author":"LD Mayer","year":"2019","unstructured":"Mayer LD, Tardi P, Louie AC. CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int J Nanomedicine. 2019. https:\/\/doi.org\/10.2147\/ijn.S139450.","journal-title":"Int J Nanomedicine"},{"key":"2025_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-022-01310-1","author":"A Detappe","year":"2023","unstructured":"Detappe A, Nguyen HV, Jiang Y, Agius MP, Wang W, Mathieu C, et al. Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma. Nat Nanotechnol. 2023. https:\/\/doi.org\/10.1038\/s41565-022-01310-1.","journal-title":"Nat Nanotechnol"},{"key":"2025_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aax1346","author":"CC Xue","year":"2020","unstructured":"Xue CC, Li MH, Zhao Y, Zhou J, Hu Y, Cai KY, et al. Tumor microenvironment-activatable Fe-doxorubicin preloaded amorphous CaCO(3) nanoformulation triggers ferroptosis in target tumor cells. Sci Adv. 2020. https:\/\/doi.org\/10.1126\/sciadv.aax1346.","journal-title":"Sci Adv"},{"key":"2025_CR32","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.7b04976","author":"M Liu","year":"2018","unstructured":"Liu M, Shen S, Wen D, Li M, Li T, Chen X, et al. Hierarchical nanoassemblies-assisted combinational delivery of cytotoxic protein and antibiotic for cancer treatment. Nano Lett. 2018. https:\/\/doi.org\/10.1021\/acs.nanolett.7b04976.","journal-title":"Nano Lett"},{"key":"2025_CR33","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.8b01071","author":"K Cheng","year":"2018","unstructured":"Cheng K, Ding Y, Zhao Y, Ye S, Zhao X, Zhang Y, et al. Sequentially responsive therapeutic peptide assembling nanoparticles for dual-targeted cancer immunotherapy. Nano Lett. 2018. https:\/\/doi.org\/10.1021\/acs.nanolett.8b01071.","journal-title":"Nano Lett"},{"key":"2025_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.02.018","author":"A Dasgupta","year":"2025","unstructured":"Dasgupta A, May JN, Klinkenberg G, Besse HC, Buhl EM, Moeckel D, et al. Multidrug micelles and sonopermeation for chemotherapy co-delivery to brain tumors. J Control Release. 2025. https:\/\/doi.org\/10.1016\/j.jconrel.2025.02.018.","journal-title":"J Control Release"},{"key":"2025_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay7785","author":"Z Xiao","year":"2020","unstructured":"Xiao Z, Su Z, Han S, Huang J, Lin L, Shuai X. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-\u03baB inhibitor for antitumor immunotherapy. Sci Adv. 2020. https:\/\/doi.org\/10.1126\/sciadv.aay7785.","journal-title":"Sci Adv"},{"key":"2025_CR36","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c09794","author":"D Liu","year":"2022","unstructured":"Liu D, Cheng Y, Qiao S, Liu M, Ji Q, Zhang BL, et al. Nano-codelivery of temozolomide and siPD-L1 to reprogram the drug-resistant and immunosuppressive microenvironment in orthotopic glioblastoma. ACS Nano. 2022. https:\/\/doi.org\/10.1021\/acsnano.1c09794.","journal-title":"ACS Nano"},{"key":"2025_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-025-01932-1","author":"K Benderski","year":"2025","unstructured":"Benderski K, Lammers T, Sofias AM. Analysis of multi-drug cancer nanomedicine. Nat Nanotechnol. 2025. https:\/\/doi.org\/10.1038\/s41565-025-01932-1.","journal-title":"Nat Nanotechnol"},{"key":"2025_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2011.07.032","author":"H Wang","year":"2011","unstructured":"Wang H, Zhao Y, Wu Y, Hu YL, Nan K, Nie G, et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011. https:\/\/doi.org\/10.1016\/j.biomaterials.2011.07.032.","journal-title":"Biomaterials"},{"key":"2025_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/adma.201703135","author":"X Liang","year":"2017","unstructured":"Liang X, Gao C, Cui L, Wang S, Wang J, Dai Z. Self-assembly of an amphiphilic Janus camptothecin-floxuridine conjugate into liposome-like nanocapsules for more efficacious combination chemotherapy in cancer. Adv Mater. 2017. https:\/\/doi.org\/10.1002\/adma.201703135.","journal-title":"Adv Mater"},{"key":"2025_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202007719","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Yue YX, Xu L, Wang Y, Geng WC, Li JJ, et al. Macrocyclic-amphiphile-based self-assembled nanoparticles for ratiometric delivery of therapeutic combinations to tumors. Adv Mater. 2021. https:\/\/doi.org\/10.1002\/adma.202007719.","journal-title":"Adv Mater"},{"key":"2025_CR41","unstructured":"Wu J, Lu Y, Lee A, Pan X, Yang X, Zhao X, et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci. 2007"},{"key":"2025_CR42","doi-asserted-by":"publisher","DOI":"10.2217\/17435889.3.6.761","author":"M Saad","year":"2008","unstructured":"Saad M, Garbuzenko OB, Minko T. Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine. 2008. https:\/\/doi.org\/10.2217\/17435889.3.6.761.","journal-title":"Nanomedicine"},{"key":"2025_CR43","doi-asserted-by":"publisher","DOI":"10.1021\/nn100690m","author":"H Meng","year":"2010","unstructured":"Meng H, Liong M, Xia T, Li Z, Ji Z, Zink JI, et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano. 2010. https:\/\/doi.org\/10.1021\/nn100690m.","journal-title":"ACS Nano"},{"key":"2025_CR44","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.9b04981","author":"Q Zhang","year":"2020","unstructured":"Zhang Q, Kuang G, He S, Lu H, Cheng Y, Zhou D, et al. Photoactivatable prodrug-backboned polymeric nanoparticles for efficient light-controlled gene delivery and synergistic treatment of platinum-resistant ovarian cancer. Nano Lett. 2020. https:\/\/doi.org\/10.1021\/acs.nanolett.9b04981.","journal-title":"Nano Lett"},{"key":"2025_CR45","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abn3883","author":"S Wang","year":"2022","unstructured":"Wang S, Wang Z, Li Z, Zhang X, Zhang H, Zhang T, et al. Amelioration of systemic antitumor immune responses in cocktail therapy by immunomodulatory nanozymes. Sci Adv. 2022. https:\/\/doi.org\/10.1126\/sciadv.abn3883.","journal-title":"Sci Adv"},{"key":"2025_CR46","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.0c01415","author":"L Wang","year":"2020","unstructured":"Wang L, Ding K, Zheng C, Xiao H, Liu X, Sun L, et al. Detachable nanoparticle-enhanced chemoimmunotherapy based on precise killing of tumor seeds and normalizing the growing soil strategy. Nano Lett. 2020. https:\/\/doi.org\/10.1021\/acs.nanolett.0c01415.","journal-title":"Nano Lett"},{"key":"2025_CR47","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abc3646","author":"J Liang","year":"2020","unstructured":"Liang J, Wang H, Ding W, Huang J, Zhou X, Wang H, et al. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity. Sci Adv. 2020. https:\/\/doi.org\/10.1126\/sciadv.abc3646.","journal-title":"Sci Adv"},{"key":"2025_CR48","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00219","author":"Z Zhao","year":"2017","unstructured":"Zhao Z, Lou S, Hu Y, Zhu J, Zhang C. A nano-in-nano polymer-dendrimer nanoparticle-based nanosystem for controlled multidrug delivery. Mol Pharm. 2017. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00219.","journal-title":"Mol Pharm"},{"key":"2025_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-023-01465-x","author":"AA Shalmani","year":"2024","unstructured":"Shalmani AA, Wang A, Ahmed Z, Sheybanifard M, Mihyar R, Buhl EM, et al. Tunable polymeric micelles for taxane and corticosteroid co-delivery. Drug Deliv Transl Res. 2024. https:\/\/doi.org\/10.1007\/s13346-023-01465-x.","journal-title":"Drug Deliv Transl Res"},{"key":"2025_CR50","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.0c02515","author":"J Chen","year":"2020","unstructured":"Chen J, Jiang Z, Xu W, Sun T, Zhuang X, Ding J, et al. Spatiotemporally targeted nanomedicine overcomes hypoxia-induced drug resistance of tumor cells after disrupting neovasculature. Nano Lett. 2020. https:\/\/doi.org\/10.1021\/acs.nanolett.0c02515.","journal-title":"Nano Lett"},{"key":"2025_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202002160","author":"X Wang","year":"2020","unstructured":"Wang X, Li M, Ren K, Xia C, Li J, Yu Q, et al. On-demand autophagy cascade amplification nanoparticles precisely enhanced oxaliplatin-induced cancer immunotherapy. Adv Mater. 2020. https:\/\/doi.org\/10.1002\/adma.202002160.","journal-title":"Adv Mater"},{"key":"2025_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s40169-018-0211-8","author":"D Ghosh","year":"2018","unstructured":"Ghosh D, Nandi S, Bhattacharjee S. Combination therapy to checkmate glioblastoma: clinical challenges and advances. Clin Transl Med. 2018. https:\/\/doi.org\/10.1186\/s40169-018-0211-8.","journal-title":"Clin Transl Med"},{"key":"2025_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01481-w","author":"D Wu","year":"2023","unstructured":"Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood-brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther. 2023. https:\/\/doi.org\/10.1038\/s41392-023-01481-w.","journal-title":"Signal Transduct Target Ther"},{"key":"2025_CR54","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3009835","author":"YJ Yu","year":"2014","unstructured":"Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, et al. Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med. 2014. https:\/\/doi.org\/10.1126\/scitranslmed.3009835.","journal-title":"Sci Transl Med"},{"key":"2025_CR55","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1307152110","author":"DT Wiley","year":"2013","unstructured":"Wiley DT, Webster P, Gale A, Davis ME. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor. Proc Natl Acad Sci U S A. 2013. https:\/\/doi.org\/10.1073\/pnas.1307152110.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113595","author":"H Baghirov","year":"2025","unstructured":"Baghirov H. Mechanisms of receptor-mediated transcytosis at the blood-brain barrier. J Control Release. 2025. https:\/\/doi.org\/10.1016\/j.jconrel.2025.113595.","journal-title":"J Control Release"},{"key":"2025_CR57","doi-asserted-by":"publisher","DOI":"10.1007\/s12274-023-5568-3","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Cheng Q, Xue Y, Yao K, Syeda MZ, Xu J, et al. LAT1 targeted brain delivery of temozolomide and sorafenib for effective glioma therapy. Nano Res. 2023. https:\/\/doi.org\/10.1007\/s12274-023-5568-3.","journal-title":"Nano Res"},{"key":"2025_CR58","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04315-4","author":"FC Lam","year":"2018","unstructured":"Lam FC, Morton SW, Wyckoff J, Vu Han TL, Hwang MK, Maffa A, et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun. 2018. https:\/\/doi.org\/10.1038\/s41467-018-04315-4.","journal-title":"Nat Commun"},{"key":"2025_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121193","author":"L Lu","year":"2021","unstructured":"Lu L, Wang K, Lin C, Yang W, Duan Q, Li K, et al. Constructing nanocomplexes by multicomponent self-assembly for curing orthotopic glioblastoma with synergistic chemo-photothermal therapy. Biomaterials. 2021. https:\/\/doi.org\/10.1016\/j.biomaterials.2021.121193.","journal-title":"Biomaterials"},{"key":"2025_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202400502","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Ma H, Li L, Sun C, Yu C, Wang L, et al. Dual-targeted novel temozolomide nanocapsules encapsulating siPKM2 inhibit aerobic glycolysis to sensitize glioblastoma to chemotherapy. Adv Mater. 2024. https:\/\/doi.org\/10.1002\/adma.202400502.","journal-title":"Adv Mater"},{"key":"2025_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.cej.2023.145514","author":"Y Sun","year":"2023","unstructured":"Sun Y, Kong J, Ge X, Mao M, Yu H, Liu J, et al. A dual receptor targeting and blood\u2013brain barrier penetrating co-drug-loaded particle mediating inhibition of oxidative phosphorylation for targeted therapy of glioblastoma. Chem Eng J. 2023. https:\/\/doi.org\/10.1016\/j.cej.2023.145514.","journal-title":"Chem Eng J"},{"key":"2025_CR62","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000207","author":"Z Zheng","year":"2020","unstructured":"Zheng Z, Zhang J, Jiang J, He Y, Zhang W, Mo X, et al. Remodeling tumor immune microenvironment (TIME) for glioma therapy using multi-targeting liposomal codelivery. J Immunother Cancer. 2020. https:\/\/doi.org\/10.1136\/jitc-2019-000207.","journal-title":"J Immunother Cancer"},{"key":"2025_CR63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015. https:\/\/doi.org\/10.1056\/NEJMoa1503093.","journal-title":"N Engl J Med"},{"key":"2025_CR64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015. https:\/\/doi.org\/10.1056\/NEJMoa1501824.","journal-title":"N Engl J Med"},{"key":"2025_CR65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-1135","author":"M Khasraw","year":"2020","unstructured":"Khasraw M, Reardon DA, Weller M, Sampson JH. PD-1 inhibitors: do they have a future in the treatment of glioblastoma? Clin Cancer Res. 2020. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-1135.","journal-title":"Clin Cancer Res"},{"key":"2025_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11719-3","author":"A Galstyan","year":"2019","unstructured":"Galstyan A, Markman JL, Shatalova ES, Chiechi A, Korman AJ, Patil R, et al. Blood-brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy. Nat Commun. 2019. https:\/\/doi.org\/10.1038\/s41467-019-11719-3.","journal-title":"Nat Commun"},{"key":"2025_CR67","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202203958","author":"Y Zou","year":"2022","unstructured":"Zou Y, Wang Y, Xu S, Liu Y, Yin J, Lovejoy DB, et al. Brain co-delivery of Temozolomide and Cisplatin for combinatorial glioblastoma chemotherapy. Adv Mater. 2022. https:\/\/doi.org\/10.1002\/adma.202203958.","journal-title":"Adv Mater"},{"key":"2025_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioactmat.2021.12.029","author":"T Wang","year":"2022","unstructured":"Wang T, Zhang H, Qiu W, Han Y, Liu H, Li Z. Biomimetic nanoparticles directly remodel immunosuppressive microenvironment for boosting glioblastoma immunotherapy. Bioact Mater. 2022. https:\/\/doi.org\/10.1016\/j.bioactmat.2021.12.029.","journal-title":"Bioact Mater"},{"key":"2025_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31799-y","author":"G Lu","year":"2022","unstructured":"Lu G, Wang X, Li F, Wang S, Zhao J, Wang J, et al. Engineered biomimetic nanoparticles achieve targeted delivery and efficient metabolism-based synergistic therapy against glioblastoma. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/s41467-022-31799-y.","journal-title":"Nat Commun"},{"key":"2025_CR70","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.4c01253","author":"Q Fan","year":"2024","unstructured":"Fan Q, Kuang L, Wang B, Yin Y, Dong Z, Tian N, et al. Multiple synergistic effects of the microglia membrane-bionic nanoplatform on mediate tumor microenvironment remodeling to amplify glioblastoma immunotherapy. ACS Nano. 2024. https:\/\/doi.org\/10.1021\/acsnano.4c01253.","journal-title":"ACS Nano"},{"key":"2025_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.12.024","author":"R Wang","year":"2022","unstructured":"Wang R, Wang X, Zhang Y, Zhao H, Cui J, Li J, et al. Emerging prospects of extracellular vesicles for brain disease theranostics. J Control Release. 2022. https:\/\/doi.org\/10.1016\/j.jconrel.2021.12.024.","journal-title":"J Control Release"},{"key":"2025_CR72","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.2c10219","author":"J Cui","year":"2023","unstructured":"Cui J, Wang X, Li J, Zhu A, Du Y, Zeng W, et al. Immune exosomes loading self-assembled nanomicelles traverse the blood-brain barrier for chemo-immunotherapy against glioblastoma. ACS Nano. 2023. https:\/\/doi.org\/10.1021\/acsnano.2c10219.","journal-title":"ACS Nano"},{"key":"2025_CR73","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c09273","author":"AJ Pickering","year":"2023","unstructured":"Pickering AJ, Lamson NG, Marand MH, Hwang W, Straehla JP, Hammond PT. Layer-by-layer polymer functionalization improves nanoparticle penetration and glioblastoma targeting in the brain. ACS Nano. 2023. https:\/\/doi.org\/10.1021\/acsnano.3c09273.","journal-title":"ACS Nano"},{"key":"2025_CR74","doi-asserted-by":"publisher","DOI":"10.1021\/jacs.4c16898","author":"AJ Pickering","year":"2025","unstructured":"Pickering AJ, Lamson NG, Marand MH, Straehla JP, Hammond PT. Convection-enhanced delivery of Auristatin-conjugated layer-by-layer nanoparticles for glioblastoma treatment. J Am Chem Soc. 2025. https:\/\/doi.org\/10.1021\/jacs.4c16898.","journal-title":"J Am Chem Soc"},{"key":"2025_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122006","author":"G Catania","year":"2023","unstructured":"Catania G, Rodella G, Vanvarenberg K, Pr\u00e9at V, Malfanti A. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival. Biomaterials. 2023. https:\/\/doi.org\/10.1016\/j.biomaterials.2023.122006.","journal-title":"Biomaterials"},{"key":"2025_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2020.04.028","author":"EG Graham-Gurysh","year":"2020","unstructured":"Graham-Gurysh EG, Murthy AB, Moore KM, Hingtgen SD, Bachelder EM, Ainslie KM. Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy. J Control Release. 2020. https:\/\/doi.org\/10.1016\/j.jconrel.2020.04.028.","journal-title":"J Control Release"},{"key":"2025_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41565-021-00879-3","author":"D Di Mascolo","year":"2021","unstructured":"Di Mascolo D, Palange AL, Primavera R, Macchi F, Catelani T, Piccardi F, et al. Conformable hierarchically engineered polymeric micromeshes enabling combinatorial therapies in brain tumours. Nat Nanotechnol. 2021. https:\/\/doi.org\/10.1038\/s41565-021-00879-3.","journal-title":"Nat Nanotechnol"},{"key":"2025_CR78","doi-asserted-by":"publisher","DOI":"10.1039\/d2bm01534j","author":"Y Wang","year":"2023","unstructured":"Wang Y, Bastiancich C, Newland B. Injectable local drug delivery systems for glioblastoma: a systematic review and meta-analysis of progress to date. Biomater Sci. 2023. https:\/\/doi.org\/10.1039\/d2bm01534j.","journal-title":"Biomater Sci"},{"key":"2025_CR79","doi-asserted-by":"publisher","DOI":"10.1021\/acs.nanolett.2c05056","author":"D Kou","year":"2023","unstructured":"Kou D, Gao Y, Li C, Zhou D, Lu K, Wang N, et al. Intranasal pathway for nanoparticles to enter the central nervous system. Nano Lett. 2023. https:\/\/doi.org\/10.1021\/acs.nanolett.2c05056.","journal-title":"Nano Lett"},{"key":"2025_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202500598","author":"Y Jia","year":"2025","unstructured":"Jia Y, Xu L, Leng S, Sun Y, Huang X, Wang Y, et al. Nose-to-brain delivery of circular RNA SCMH1-loaded lipid nanoparticles for ischemic stroke therapy. Adv Mater. 2025. https:\/\/doi.org\/10.1002\/adma.202500598.","journal-title":"Adv Mater"},{"key":"2025_CR81","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.3c01375","author":"M Farheen","year":"2023","unstructured":"Farheen M, Akhter MH, Chitme H, Suliman M, Jaremko M, Emwas AH. Surface-modified biobased polymeric nanoparticles for dual delivery of doxorubicin and gefitinib in glioma cell lines. ACS Omega. 2023. https:\/\/doi.org\/10.1021\/acsomega.3c01375.","journal-title":"ACS Omega"},{"key":"2025_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.08.048","author":"X Zhao","year":"2023","unstructured":"Zhao X, Ni S, Song Y, Hu K. Intranasal delivery of Borneol\/R8dGR peptide modified PLGA nanoparticles co-loaded with curcumin and cisplatin alleviate hypoxia in pediatric brainstem glioma which improves the synergistic therapy. J Control Release. 2023. https:\/\/doi.org\/10.1016\/j.jconrel.2023.08.048.","journal-title":"J Control Release"},{"key":"2025_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2024.12.058","author":"J Koo","year":"2025","unstructured":"Koo J, Shin Y, Jeon H, Cheong J, Cho S, Park C, et al. Enhancing glioblastoma therapy via intranasal administration of highly potent cell-penetrating peptide decorated nanoparticles. J Control Release. 2025. https:\/\/doi.org\/10.1016\/j.jconrel.2024.12.058.","journal-title":"J Control Release"},{"key":"2025_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115196","author":"Y Chen","year":"2024","unstructured":"Chen Y, Zhang C, Huang Y, Ma Y, Song Q, Chen H, et al. Intranasal drug delivery: the interaction between nanoparticles and the nose-to-brain pathway. Adv Drug Deliv Rev. 2024. https:\/\/doi.org\/10.1016\/j.addr.2024.115196.","journal-title":"Adv Drug Deliv Rev"},{"key":"2025_CR85","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.1c07587","author":"K Wang","year":"2021","unstructured":"Wang K, Kumar US, Sadeghipour N, Massoud TF, Paulmurugan R. A microfluidics-based scalable approach to generate extracellular vesicles with enhanced therapeutic microRNA loading for intranasal delivery to mouse glioblastomas. ACS Nano. 2021. https:\/\/doi.org\/10.1021\/acsnano.1c07587.","journal-title":"ACS Nano"},{"key":"2025_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101244","author":"SW Lin","year":"2024","unstructured":"Lin SW, Yu CP, Tsai JC, Shyong YJ. Delivery of extracellular vesicles loaded with immune checkpoint inhibitors for immunotherapeutic management of glioma. Mater Today Bio. 2024. https:\/\/doi.org\/10.1016\/j.mtbio.2024.101244.","journal-title":"Mater Today Bio"},{"key":"2025_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45818-7","author":"A Carpentier","year":"2024","unstructured":"Carpentier A, Stupp R, Sonabend AM, Dufour H, Chinot O, Mathon B, et al. Repeated blood-brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I\/II clinical trial. Nat Commun. 2024. https:\/\/doi.org\/10.1038\/s41467-024-45818-7.","journal-title":"Nat Commun"},{"key":"2025_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.ultrasmedbio.2021.01.014","author":"M Olsman","year":"2021","unstructured":"Olsman M, Sereti V, M\u00fchlenpfordt M, Johnsen KB, Andresen TL, Urquhart AJ, et al. Focused ultrasound and microbubble treatment increases delivery of transferrin receptor-targeting liposomes to the brain. Ultrasound Med Biol. 2021. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2021.01.014.","journal-title":"Ultrasound Med Biol"},{"key":"2025_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31791-4","author":"U Herrlinger","year":"2019","unstructured":"Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019. https:\/\/doi.org\/10.1016\/s0140-6736(18)31791-4.","journal-title":"Lancet"},{"key":"2025_CR90","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac116","author":"M Lim","year":"2022","unstructured":"Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro Oncol. 2022. https:\/\/doi.org\/10.1093\/neuonc\/noac116.","journal-title":"Neuro Oncol"},{"key":"2025_CR91","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac099","author":"A Omuro","year":"2023","unstructured":"Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro Oncol. 2023. https:\/\/doi.org\/10.1093\/neuonc\/noac099.","journal-title":"Neuro Oncol"},{"key":"2025_CR92","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-20-2500","author":"L Nayak","year":"2021","unstructured":"Nayak L, Molinaro AM, Peters K, Clarke JL, Jordan JT, de Groot J, et al. Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for patients with recurrent glioblastoma. Clin Cancer Res. 2021. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-2500.","journal-title":"Clin Cancer Res"},{"key":"2025_CR93","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"2025_CR94","unstructured":"FutureMarketInsights. Breast Cancer Drug Market 2025 [Available from: https:\/\/www.futuremarketinsights.com\/reports\/breast-cancer-drug-market."},{"key":"2025_CR95","unstructured":"FutureMarketInsights. Lung Cancer Therapeutics Market 2025 [Available from: https:\/\/www.futuremarketinsights.com\/reports\/lung-cancer-therapeutics-market."},{"key":"2025_CR96","unstructured":"FutureMarketInsights. Glioblastoma Treatment Drugs Market 2025 [Available from: https:\/\/www.futuremarketinsights.com\/reports\/glioblastoma-treatment-drugs-market."},{"key":"2025_CR97","unstructured":"Merck. Modifi Biosciences Acquired by Merck 2024 [Available from: https:\/\/www.merck.com\/bdl_item\/modifi-biosciences-acquired-by-merck\/."},{"key":"2025_CR98","unstructured":"Pharmaceuticals J. Jazz Pharmaceuticals Completes Acquisition of Chimerix 2025 [Available from: https:\/\/investor.jazzpharma.com\/news-releases\/news-release-details\/jazz-pharmaceuticals-completes-acquisition-chimerix\/."},{"key":"2025_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-025-00148-1","author":"A Mullard","year":"2025","unstructured":"Mullard A. First protease activator secures FDA approval for rare brain cancer. Nat Rev Drug Discov. 2025. https:\/\/doi.org\/10.1038\/d41573-025-00148-1.","journal-title":"Nat Rev Drug Discov"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-02025-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-02025-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-02025-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:10:29Z","timestamp":1765995029000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-02025-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":99,"alternative-id":["2025"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-02025-1","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"17 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethical approval or consent to participate was required to this review paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to the publication of this review paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}